Article
SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition.
Cancer research - 15 Aug 2025
Murimwa Gilbert Z, Williams Natalie E, Alzhanova Dina, Mohammadi Amir, Westcott Jill M, Beato Francisca, Dai Ruifan, Nivelo Luis, Rossi Francesca, Fleming Henry K, Tassielli Alexandra F, Yazgan Zeynep, Toombs Jason E, Fleming Jason B, Singhi Aatur D, Ethun Cecilia G, Huang Huocong, Brekken Rolf A
Abstract excerpt
The 5-year overall survival rate for pancreatic cancer remains ∼13%, underscoring the urgent need for improved treatment strategies. TGFβ is a promising target due to its significant involvement in the desmoplasia, immune suppression, and chemoresistance characteristics of pancreatic cancer. More than 300 clinical trials targeting TGFβ have been conducted in unselected patient cohorts; however, none of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.